Financial Management Professionals Inc. Sells 89 Shares of Johnson & Johnson (NYSE:JNJ)

Financial Management Professionals Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 11.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 672 shares of the company’s stock after selling 89 shares during the quarter. Financial Management Professionals Inc.’s holdings in Johnson & Johnson were worth $100,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Calamos Wealth Management LLC increased its stake in Johnson & Johnson by 2.0% in the third quarter. Calamos Wealth Management LLC now owns 15,393 shares of the company’s stock valued at $2,292,000 after acquiring an additional 301 shares during the period. Howland Capital Management LLC boosted its position in Johnson & Johnson by 1.1% in the third quarter. Howland Capital Management LLC now owns 143,824 shares of the company’s stock valued at $21,413,000 after buying an additional 1,576 shares in the last quarter. State of Michigan Retirement System boosted its position in Johnson & Johnson by 2.3% in the third quarter. State of Michigan Retirement System now owns 878,487 shares of the company’s stock valued at $130,789,000 after buying an additional 20,100 shares in the last quarter. Lowe Brockenbrough & Co. Inc. boosted its position in Johnson & Johnson by 0.3% in the third quarter. Lowe Brockenbrough & Co. Inc. now owns 84,590 shares of the company’s stock valued at $12,594,000 after buying an additional 275 shares in the last quarter. Finally, Naples Global Advisors LLC boosted its position in Johnson & Johnson by 6.7% in the third quarter. Naples Global Advisors LLC now owns 27,771 shares of the company’s stock valued at $4,135,000 after buying an additional 1,746 shares in the last quarter. 67.44% of the stock is currently owned by institutional investors and hedge funds.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

JNJ opened at $137.11 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The company has a market cap of $360.95 billion, a price-to-earnings ratio of 21.56, a price-to-earnings-growth ratio of 3.14 and a beta of 0.68. The firm has a 50 day simple moving average of $146.71 and a 200 day simple moving average of $147.21. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 35.10%. The business had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. During the same period in the previous year, the firm posted $2.12 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.7% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 7.99 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.01 dividend. This represents a $4.04 annualized dividend and a yield of 2.95%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s payout ratio is presently 46.54%.

A number of equities analysts have commented on the stock. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $161.00 to $164.00 in a research report on Monday, July 20th. Bank of America restated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 20th. Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. Finally, Cantor Fitzgerald upped their target price on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus price target of $164.93.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also: What are no-load funds?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.